🚀 VC round data is live in beta, check it out!
HCW Biologics Valuation Multiples
Discover revenue and EBITDA valuation multiples for HCW Biologics and similar public comparables like CASI Pharmaceuticals, Guard Therapeutics, Double Bond, Cannabis Poland and more.
HCW Biologics Overview
About HCW Biologics
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Founded
2018
HQ
Employees
36
Website
Sectors
Financials (LTM)
EV
$8M
HCW Biologics Financials
HCW Biologics reported last 12-month revenue of $11K.
In the same LTM period, HCW Biologics generated ($11K) in gross profit and had net loss of ($21M).
Revenue (LTM)
HCW Biologics P&L
In the most recent fiscal year, HCW Biologics reported revenue of $54K and EBITDA of ($6M).
HCW Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11K | XXX | $54K | XXX | XXX | XXX |
| Gross Profit | ($11K) | XXX | $11K | XXX | XXX | XXX |
| Gross Margin | (103%) | XXX | 20% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($6M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (10451%) | XXX | XXX | XXX |
| EBIT Margin | (126802%) | XXX | (20758%) | XXX | XXX | XXX |
| Net Profit | ($21M) | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | (192177%) | XXX | (14677%) | XXX | XXX | XXX |
| Net Debt | — | — | $5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
HCW Biologics Stock Performance
HCW Biologics has current market cap of $3M, and enterprise value of $8M.
Market Cap Evolution
HCW Biologics' stock price is $0.44.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8M | $3M | 0.0% | XXX | XXX | XXX | $-1.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHCW Biologics Valuation Multiples
HCW Biologics trades at 719.1x EV/Revenue multiple, and (1.4x) EV/EBITDA.
EV / Revenue (LTM)
HCW Biologics Financial Valuation Multiples
As of April 19, 2026, HCW Biologics has market cap of $3M and EV of $8M.
Equity research analysts estimate HCW Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HCW Biologics has a P/E ratio of (0.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV (current) | $8M | XXX | $8M | XXX | XXX | XXX |
| EV/Revenue | 719.1x | XXX | 143.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.4x) | XXX | XXX | XXX |
| EV/EBIT | (0.6x) | XXX | (0.7x) | XXX | XXX | XXX |
| EV/Gross Profit | (699.3x) | XXX | 719.1x | XXX | XXX | XXX |
| P/E | (0.1x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified HCW Biologics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
HCW Biologics Margins & Growth Rates
HCW Biologics' revenue in the last fiscal year declined by (98%).
HCW Biologics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
HCW Biologics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (98%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (10451%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (80%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10304% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 59916% | XXX | 10426% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 20778% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
HCW Biologics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| HCW Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| CASI Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Guard Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Double Bond | XXX | XXX | XXX | XXX | XXX | XXX |
| Cannabis Poland | XXX | XXX | XXX | XXX | XXX | XXX |
| Biosergen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HCW Biologics M&A Activity
HCW Biologics acquired XXX companies to date.
Last acquisition by HCW Biologics was on XXXXXXXX, XXXXX. HCW Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by HCW Biologics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHCW Biologics Investment Activity
HCW Biologics invested in XXX companies to date.
HCW Biologics made its latest investment on XXXXXXXX, XXXXX. HCW Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by HCW Biologics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout HCW Biologics
| When was HCW Biologics founded? | HCW Biologics was founded in 2018. |
| Where is HCW Biologics headquartered? | HCW Biologics is headquartered in United States. |
| How many employees does HCW Biologics have? | As of today, HCW Biologics has over 36 employees. |
| Who is the CEO of HCW Biologics? | HCW Biologics' CEO is Hing C. Wong. |
| Is HCW Biologics publicly listed? | Yes, HCW Biologics is a public company listed on Nasdaq. |
| What is the stock symbol of HCW Biologics? | HCW Biologics trades under HCWB ticker. |
| When did HCW Biologics go public? | HCW Biologics went public in 2021. |
| Who are competitors of HCW Biologics? | HCW Biologics main competitors are CASI Pharmaceuticals, Guard Therapeutics, Double Bond, Cannabis Poland. |
| What is the current market cap of HCW Biologics? | HCW Biologics' current market cap is $3M. |
| What is the current revenue of HCW Biologics? | HCW Biologics' last 12 months revenue is $11K. |
| What is the current EV/Revenue multiple of HCW Biologics? | Current revenue multiple of HCW Biologics is 719.1x. |
| Is HCW Biologics profitable? | No, HCW Biologics is not profitable. |
| What is the current net income of HCW Biologics? | HCW Biologics' last 12 months net income is ($21M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.